Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2011-06-28
2011-06-28
Yu, Misook (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S388850, C530S391100, C530S391700
Reexamination Certificate
active
07968687
ABSTRACT:
This invention relates to CD 19 binding agents and methods of using such CD 19 binding agents for treating disease.
REFERENCES:
patent: 5635483 (1997-06-01), Pettit et al.
patent: 5686072 (1997-11-01), Uhr et al.
patent: 5767237 (1998-06-01), Sakakibara et al.
patent: 5780588 (1998-07-01), Pettit et al.
patent: 6214345 (2001-04-01), Firestone et al.
patent: 6884869 (2005-04-01), Senter et al.
patent: 7109304 (2006-09-01), Hansen et al.
patent: 7462352 (2008-12-01), Hansen et al.
patent: 2004/0126363 (2004-07-01), Jensen et al.
patent: 2004/0136908 (2004-07-01), Olson et al.
patent: 2005/0238649 (2005-10-01), Doronina et al.
patent: 2006/0024317 (2006-02-01), Boyd et al.
patent: 2006/0074008 (2006-04-01), Senter et al.
patent: 2006/0233791 (2006-10-01), Tedder et al.
patent: 2006/0233794 (2006-10-01), Law et al.
patent: 2006/0240008 (2006-10-01), Benyunes
patent: 2006/0280738 (2006-12-01), Tedder
patent: 2007/0154473 (2007-07-01), Super et al.
patent: 2008/0138336 (2008-06-01), Damschroder et al.
patent: 2008/0260731 (2008-10-01), Bernett et al.
patent: WO 2004/010957 (2004-02-01), None
patent: WO2006113665 (2006-10-01), None
patent: WO2006138737 (2006-12-01), None
patent: WO 2007/002223 (2007-01-01), None
patent: WO 2008/022152 (2008-02-01), None
Al-Lazikani et al., “Standard Conformations for the Canonical Structures of Immunoglobulins,”J. Mol. Biol., 1997, 273, 927-948.
Almagro et al., “Structural differences between the repertoires of mouse and human germline genes and their evolutionary implications,”Immunogenetics, 1998, 47, 355-363.
Benjamin et al., “Humanized Anti-CD19 Auristatin Antibody-Drug Conjugates Display Potent Antitumor Activity in Preclinical Models of B-Cell Malignancies,”Proceedings of the AACR-NCI-EORTC, San Francisco, CA, 2007, Abstract B60.
Chari et al., “Enhancement of the Selectivity and Antitumor Efficacy of a CC-1065 Analogue through Immunoconjugate Formation,”Cancer Research, 1995, 55, 4079-4084.
Chothia et al., “Domain Association in Immunoglobulin Molecules the Packing of Variable Domains,”J. Mol. Biol., 1985, 186, 651-663.
Chothia et al., “Canonical Structures for the Hypervariable Regions of Immunoglobulins,”J. Mol. Biol., 1987, 196, 901-917.
Chothia et al., “Conformations of immunoglobulin hypervariable regions,”Nature, 1989, 342, 877-883.
Du et al., “Differential Cellular Internalization of Anti-CD19 and—CD22 Immunotoxins Results in Different Cytotoxic Activity,”Cancer Res., 2008, 68(15), 6300-6305.
Flavell et al., “Preclinical studies with the anti-CD19-Saporin immunotoxin BU12-SAPORIN for the treatment of human-B-cell tumours,”British Journal of Cancer, 1995, 72, 1373-1379.
Flavell et al., “Therapy of Human B-Cell Lymphoma Bearing Scid Mice is more effective with Anti-CD19- and Anti-CD38-Saporin Immunotoxins used in combination than with either Immunotoxin used alone,”Int. J. Cancer, 1995, 62, 337-344.
Gerber et al., “Potent antitumor activity of the anti-CD19 auristatin antibody-drug conjugate SGN-19A in rituximab sensitive and resistant lymphomas,”Proceedings of the AACR-NCI-EORTC, Geneva, Switzerland, 2008, Abstract 507.
Goulet et al., “Conjugation of Blocked Ricin to an Anti-CD19 Monoclonal Antibody Increases Antibody-Induced Cell Calcium Mobilization and CD19 Internalization,”Blood, 1997, 90(6), 2364-2375.
Hooijberg et al., “Enhanced Antitumor Effects of CD20 over CD19 Monoclonal Antibodies in a Nude Mouse Xenograft Model,”Cancer Research, 1995, 55, 840-846.
Ingle et al., “High CD21 expression inhibits internalization of anti-CD19 antibodies and cytotoxicity of an anti-CD19-drug conjugate,”British Journal of Haematology, 2007, 140, 46-58.
Iwahashi et al., “CDR substitutions of a humanized monoclonal antibody (CC49): contributions of individual CDRs to antigen binding and immunogenicity,”Molecular Immunology, 1999, 36, 1079-1091.
Lee et al., “Complement Component C3d-Antigen Complexes Can Either Augment or Inhibit B Lymphocyte Activation and Humoral Immunity in Mice Depending on the Degree of CD21/CD19 Complex Engagement,”The Journal of Immunology, 2005, 175, 8011-8023.
Liu et al., “Cure of Multidrug-Resistant Human B-Cell Lymphoma Xenografts by Combinations of Anti-B4-Blocked Ricin and Chemotherapeutic Drugs,”Blood, 1996, 87(9), 3892-3898.
Messmann et al., “A Phase I Study of Combination Therapy with Immunotoxins IgG-HD37-Deglycosylated Ricin A Chain (dgA) and IgG-RFB4-dgA (Combotox) in Patients with Refractory CD19(+), CD22(+) B Cell Lymphoma,”Clinical Cancer Research, 2000, 6, 1302-1313.
Mitchell et al., “Targeting Primary Human Ph+ B-Cell Precursor Leukemia-Engrafted SCID Mice Using Radiolabeled Anti-CD19 Monoclonal Antibodies,”J. Nucl. Med., 2003, 44, 1105-1112.
Miyazaki et al., “Synthesis and Antitumor Activity of Novel Dolastatin 10 Analogs,”Chem. Pharm. Bull., 1995, 43(10), 1706-1718.
Padlan et al., “Identification of specificity-determining residues in antibodies,”FASEB, 1995, 9, 133-139.
Pietersz et al., “In vitro and in vivo antitumour activity of a chimeric anti-CD19 antibody,”Cancer Immunol Immunother, 1995, 41, 53-60.
Shah et al., “Anti-B4-blocked Ricin Immunotoxin Shows Therapeutic Efficacy in Four Different SCID Mouse Tumor Models,”Cancer Research, 1993, 53, 1360-1367.
Stone et al., “A Phase I Study of Bolus Versus Continuous Infusion of the Anti-CD19 Immunotoxin, IgG-HD37-dgA, in Patients With B-Cell Lymphoma,”Blood, 1996, 88(4), 1188-1197.
Tamura et al., “Structural Correlates of an Anticarcinoma Antibody: Identification of Specificity-Determining Residues (SDRs) and Development of a Minimally Immunogenic Antibody Variant by Retention of SDRs Only,”The Journal of Immunology, 2000, 164, 1432-1441.
Tedder et al., “Fcγ receptor-dependent effector mechanisms regulate CD19 and CD20 antibody immunotherapies for B lymphocyte malignancies and autoimmunity,”Springer Semin Immun, 2006, 28, 351-364.
Tomlinson et al., “The structural repertoire of the human Vκ domain,”The EMBO Journal, 1995, 14(18), 4628-4638.
Tsimberidou et al., “Anti-B4 Blocked Ricin Post Chemotherapy in Patients with Chronic Lymphocytic Leukemia—Long-term Follow-up of a Monoclonal Antibody-based Approach to Residual Disease,”Leukemia&Lymphoma, 2003, 44(10), 1719-1725.
Vallera et al., “Radiotherapy of CD19 Expressing Daudi Tumors in Nude Mice with Yttrium-90-Labeled Anti-CD19 Antibody,”Cancer Biotherapy&Radiopharmaceuticals, 2004, 19(1), 11-23.
Veillette et al, “Negative Regulation of Immunoreceptor Signaling,”Annu. Rev. Immunol., 2002, 20, 669-707.
Yazawa et al., “Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease,”PNAS, 2005, 102(42), 15178-15183.
Benjamin Dennis
Carter Paul
Cerveny Charles G.
McDonagh Charlotte
Alston and Bird LLP
Duffy Brad
Seattle Genetics Inc.
Yu Misook
LandOfFree
CD19 binding agents and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with CD19 binding agents and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and CD19 binding agents and uses thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2619660